Hologic (HOLX) PT Lowered to $45.00

Hologic (NASDAQ:HOLX) had its price target reduced by Piper Jaffray Companies to $45.00 in a research note published on Thursday, The Fly reports. They currently have an overweight rating on the medical equipment provider’s stock. Piper Jaffray Companies also issued estimates for Hologic’s Q1 2019 earnings at $0.57 EPS, Q2 2019 earnings at $0.58 EPS, Q3 2019 earnings at $0.62 EPS, Q4 2019 earnings at $0.63 EPS, FY2019 earnings at $2.39 EPS, Q1 2020 earnings at $0.65 EPS, Q2 2020 earnings at $0.64 EPS, Q3 2020 earnings at $0.68 EPS, Q4 2020 earnings at $0.69 EPS and FY2020 earnings at $2.67 EPS.

HOLX has been the subject of a number of other research reports. Bank of America cut shares of Hologic from a buy rating to a neutral rating and cut their price objective for the company from $47.00 to $42.00 in a report on Thursday, September 13th. BidaskClub cut shares of Hologic from a hold rating to a sell rating in a report on Thursday, August 16th. Zacks Investment Research cut shares of Hologic from a hold rating to a sell rating in a report on Tuesday, October 9th. Canaccord Genuity lifted their price objective on shares of Hologic from $40.00 to $41.00 and gave the company a hold rating in a report on Thursday, September 27th. Finally, Cowen reaffirmed a buy rating and issued a $45.00 price objective on shares of Hologic in a report on Wednesday, August 1st. One analyst has rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company’s stock. Hologic currently has a consensus rating of Hold and a consensus target price of $44.41.

HOLX traded down $0.68 on Thursday, reaching $41.78. The stock had a trading volume of 2,607,170 shares, compared to its average volume of 2,298,622. Hologic has a 12-month low of $35.10 and a 12-month high of $45.09. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29. The stock has a market capitalization of $11.01 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 1.84 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 7th. The medical equipment provider reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.01). Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. The firm had revenue of $813.50 million during the quarter, compared to analysts’ expectations of $808.63 million. During the same period in the previous year, the firm posted $0.50 EPS. The firm’s quarterly revenue was up 1.3% on a year-over-year basis. On average, equities research analysts forecast that Hologic will post 2.41 earnings per share for the current year.

In other news, Director Christiana Stamoulis sold 30,967 shares of the business’s stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $40.70, for a total transaction of $1,260,356.90. Following the completion of the sale, the director now owns 66,006 shares of the company’s stock, valued at $2,686,444.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Karleen Marie Oberton sold 1,312 shares of the business’s stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $41.90, for a total transaction of $54,972.80. Following the sale, the chief financial officer now directly owns 10,206 shares of the company’s stock, valued at approximately $427,631.40. The disclosure for this sale can be found here. Insiders have sold 49,519 shares of company stock valued at $2,003,965 in the last three months. Corporate insiders own 0.79% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Hologic by 0.9% during the third quarter. BlackRock Inc. now owns 18,773,720 shares of the medical equipment provider’s stock worth $769,349,000 after purchasing an additional 164,937 shares in the last quarter. Parnassus Investments CA grew its stake in Hologic by 3.4% during the 2nd quarter. Parnassus Investments CA now owns 16,241,334 shares of the medical equipment provider’s stock valued at $645,593,000 after acquiring an additional 535,745 shares in the last quarter. Victory Capital Management Inc. grew its stake in Hologic by 5.1% during the 2nd quarter. Victory Capital Management Inc. now owns 5,813,464 shares of the medical equipment provider’s stock valued at $231,085,000 after acquiring an additional 282,510 shares in the last quarter. FMR LLC grew its stake in Hologic by 6.4% during the 3rd quarter. FMR LLC now owns 2,438,184 shares of the medical equipment provider’s stock valued at $99,916,000 after acquiring an additional 146,726 shares in the last quarter. Finally, Partner Fund Management L.P. grew its stake in Hologic by 20.3% during the 2nd quarter. Partner Fund Management L.P. now owns 1,892,703 shares of the medical equipment provider’s stock valued at $75,235,000 after acquiring an additional 319,846 shares in the last quarter. 98.74% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Read More: Determine Your Level of Risk Tolerance

The Fly

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply